All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
This month, in a Letter to the Editor of Haematologica, Pedro Henrique Prata from the Hématologie Clinique, Hôpital Saint Louis, Paris, France, and colleagues reported results from their retrospective study, which evaluated the outcomes of patients with nucleophosmin-1 (NPM1) mutated acute myeloid leukemia (AML) unfit for intensive chemotherapy (IC) who are treated with hypomethylating agents (HMAs).
In total, 71 NPM1 positive AML patients who were treated with HMAs between 2007 and 2016 in eight European and one American center were analyzed in this study.
Thirty-four patients (median age = 77 years; range 55–85) received upfront HMAs. They had been considered unfit for intensive chemotherapy based on age > 80, cardiac or other comorbidities, and according to each institution’s recommendations. Azacitidine (AZA) was administered in 17 patients, decitabine (DAC) in 10 patients, and seven patients received guadecitabine. Patients in this group were compared with 92 NPM1 negative AML patients treated upfront with azacitidine between 2007 and 2012.
Thirty-seven patients (median age = 65 years; range 36–87) received HMAs as second or subsequent line of treatment. Patients in this group had previously received anthracycline or cytarabine-based chemotherapy, seven patients had allogeneic, and one autologous stem cell transplantation. AZA was administered in 30 patients, DAC in seven patients and none of the patients received guadecitabine.
In summary, this is the first study evaluating HMAs in NPM1 positive AML. The results of this retrospective study indicate that HMAs did not yield positive results in terms of long-term survival as first-line treatment of NPM1 positive AML. The authors suggested that NPM1 status should be added to first-line treatment decision factors in elderly AML. They further noted that “NPM1 status could contribute to physician’s decisions to administer IC rather than HMA when no major contraindications to IC exist.”
References